How we got here
During the 2023-2024 GLP-1 shortage, FDA allowed both 503A pharmacies (state-licensed, patient-specific) and 503B outsourcing facilities (commercial-scale) to compound semaglutide and tirzepatide. This was a temporary "drug-in-shortage" allowance under section 503B(d)(2).
In October 2024 FDA declared the shortage resolved. 503B facilities were given a wind-down period; many continued operating into 2026 under various legal interpretations.
On April 30, 2026, FDA published a proposed rule formally adding semaglutide and tirzepatide to the "do not compound" list for 503B facilities. The 60-day public comment period closes June 29, 2026.
503A vs. 503B: why the distinction matters
503A pharmacies are traditional state-licensed pharmacies that compound on a per-patient basis. They require an individual prescription before compounding. Legal under section 503A of the FDCA. NOT directly affected by the April 30 proposed rule.
503B outsourcing facilities are FDA-registered commercial compounders that can produce drugs in bulk for office-use, telehealth platforms, and clinics — without per-patient prescriptions. They operate under section 503B and are explicitly the target of the proposed rule.
Most major compounded-GLP-1 telehealth services (some of the lowest-priced subscription products) are supplied by 503B facilities. These are the products most at risk.
What to do right now if you are on compounded GLP-1
1. Confirm where your medication comes from. Ask your telehealth provider: is this from a 503A or 503B compounder? Reputable services disclose this in the FAQ or onboarding email.
2. Check your prescription cadence. Some 503A pharmacies operate on a fixed 30-day cycle requiring fresh prescriptions monthly. If your service supplies 90-day fills with no monthly refill, it is likely 503B-sourced.
3. Price the brand-name alternative. Wegovy via the Novo savings card runs $499/month commercially insured; Zepbound via LillyDirect $349-499. Oral Wegovy via Hims at $149/month is now the lowest-priced FDA-approved option.
4. Document baseline labs and weight. If you have to pivot mid-treatment, your prescriber needs a clean record of where you are.
What the timeline likely looks like
June 29, 2026: comment period closes. Industry groups, patient advocacy organizations, and pharmacies submit responses.
August-October 2026 (typical FDA pace): FDA reviews comments and issues either a final rule, a revised proposed rule, or withdraws the proposal.
If finalized as proposed: 503B facilities have ~90-180 days to wind down. Existing prescriptions can be filled through that wind-down window; new ones likely cannot be filled by 503B facilities after the effective date.
If 503A pharmacies remain compliant under existing law, patient-specific compounded prescriptions can continue indefinitely. Pricing on those typically runs higher ($250-400/month) than 503B subscription products ($99-199).
Frequently asked questions
- Is compounded semaglutide legal in 2026?
- Patient-specific compounding by 503A pharmacies remains legal. 503B bulk compounding is the subject of FDA's April 30, 2026 proposed rule — comment period closes June 29. Final rule expected late 2026.
- What happens if I am on compounded GLP-1 when the rule finalizes?
- Wind-down provisions typically allow 90-180 days for existing patients. Your provider should pivot you to brand-name (Wegovy, Zepbound, oral Wegovy) or to a 503A-supplied compounded product. Plan for a price increase to $149+/month at minimum.
- Why is FDA targeting compounded GLP-1s now?
- Patient safety (manufacturing variability), insufficient evidence of bioequivalence to brand-name, and the fact that the shortage that justified compounding has resolved. Brand-name supply now meets demand.
- Can I still get cheap GLP-1 if compounded is restricted?
- Yes — Hims oral Wegovy ($149/mo), LillyDirect Zepbound ($349-499/mo), and Medicare GLP-1 Bridge ($50/mo from July 1) all provide lower-cost FDA-approved alternatives. Compare providers for current pricing.
- Should I switch off compounded semaglutide now or wait?
- No need to panic-switch. Final rule is months away. Use this time to: confirm sourcing, save 1-2 months of medication if your service allows, and have a conversation with your prescriber about brand-name as backup.
Disclosure: Glpverdict is affiliate-funded but editorially independent. Some links above are sponsored — we may earn a commission if you sign up with a partner provider. This does not affect our editorial rankings or medical review.
